- The Flexibility Papers No. 3: Old Drugs, New Possibilities – Repurposing as Part of the Rare Disease Framework November 6, 2026
- The Citizen Petition That Reads Like Legislative History: ROS1/RET Meets the Precision Oncology Modernization Act November 5, 2026
- A Day Late, A Buck Short: Or How to Lose PTE Without Really Trying November 3, 2026
- The Flexibility Papers, No. 2: Beyond Listening—Making Patient Input Matter November 1, 2026
- DEA Clarifies Direct Delivery of Prescribed Controlled Substances to Practitioners October 30, 2026
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
FDA’s Chief Counsel, Ralph Tyler, Set to Leave FDA
June 30, 2011About 18 months after coming to FDA to serve as Chief Counsel, Ralph Tyler will be leaving the Agency, according to an FDA-wide e-mail sent out on June 30th by FDA Commissioner Margaret Hamburg. Prior to joining FDA, Mr. Tyler served as Insurance Commissioner of the State of Maryland (see our previous post here). Mr. Tyler's last day at FDA will be August 5, 2011. We understand that an Acting FDA Chief Counsel has not yet been named.
Categories: FDA News
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- Best Lawyers in America® – 2026
- Ranked in Chambers USA – 2025
- The Flexibility Papers No. 3: Old Drugs, New Possibilities – Repurposing as Part of the Rare Disease Framework November 6, 2026
- The Citizen Petition That Reads Like Legislative History: ROS1/RET Meets the Precision Oncology Modernization Act November 5, 2026
- A Day Late, A Buck Short: Or How to Lose PTE Without Really Trying November 3, 2026
- The Flexibility Papers, No. 2: Beyond Listening—Making Patient Input Matter November 1, 2026
- DEA Clarifies Direct Delivery of Prescribed Controlled Substances to Practitioners October 30, 2026
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized